Compounded Semaglutide 2026
Is it still legal? What did the FDA enforcement shift actually change? Where can you still get it — and at what price?
FDA Enforcement Update — Semaglutide is more restricted than tirzepatide in 2026
- • March 2025: FDA declared semaglutide shortage officially resolved — removing the primary legal basis for 503A scale compounding
- • April 1, 2026: FDA ended enforcement discretion for 503A pharmacies compounding semaglutide copies at telehealth scale
- • April 30, 2026: FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list
- • June 29, 2026: Public comment deadline on the April 30 proposal
- • What still may be available: Patient-specific 503A compounding with documented clinical justification (allergy, custom strength, or other criterion)
Sources: FDA.gov official guidance and Federal Register notices. Always confirm current availability with your telehealth provider.
What Is Compounded Semaglutide?
Semaglutide is the active ingredient in Ozempic (diabetes) and Wegovy (obesity) — FDA-approved GLP-1 receptor agonists manufactured by Novo Nordisk. Compounded semaglutide is a version of the same active ingredient produced by state-licensed compounding pharmacies operating under FDA exemptions, rather than manufactured through Novo Nordisk's regulated process.
Compounded semaglutide is NOT FDA-approved. It is produced under either 503A (patient-specific, prescription-based) or 503B (outsourcing facility, batch-scale) frameworks. Neither is equivalent to the FDA approval process for branded drugs.
Compounded Semaglutide
- Typically 70–90% cheaper than branded Ozempic/Wegovy
- Available via telehealth without prior insurance authorization
- NOT FDA-approved — different manufacturing standards
- Legal basis has narrowed significantly since March 2025
Branded Ozempic / Wegovy
- FDA-approved with rigorous clinical trial data (STEP-1 through STEP-8)
- Consistent formulation, pharmacokinetics, and QC standards
- $800–$1,400+/mo without insurance (retail list price)
- Requires insurance prior authorization for most plans
Verified Pricing — Active Providers
Verified on brand site May 6, 2026Strut Health
Lowest Entry Price$99/mo auto-refill · $119/mo month-to-month
Oral compounded semaglutide at the lowest verified entry price in our Katalys stack. Async no-video physician review, LegitScript + HIPAA compliant, 2-day shipping. Best for cost-sensitive patients open to oral format.
Notable for
- $99/mo lowest verified entry price
- No video visit — async physician review
- Multi-vertical (hair, skin, ED)
- Free shipping + follow-up
Watch for
- Oral-only — no injectable option
- CR 7.12% but lower absolute volume than TMates
TMates
#1 EPC in Stack$249/mo · 3 mo $217/mo · 6 mo $175/mo · 12 mo $158/mo
Highest EPC ($16.09) and conversion rate (6.43%) in our entire Katalys account. Same price across all doses — no titration upcharge. Available in both injectable and oral drop formats. The #1 overall pick for affiliate performance.
Notable for
- $16.09 EPC — #1 in entire Katalys account
- 6.43% conversion rate
- Same price all doses (0.25–2.4mg)
- Injectable + oral options
Watch for
- Best per-month pricing requires 12-month commitment
- No branded Wegovy/Ozempic
Embody
GLP-1 Gum Unique Format$149 intro month · $299/mo flat ongoing (any dose)
The only provider in our stack offering GLP-1 in gum format — a needle-free daily chew. Also offers traditional injections at flat $299/mo with no titration upcharge. Second-highest EPC ($4.60) in our Katalys stack.
Notable for
- Unique GLP-1 gum format (no needle)
- Flat-rate $299/mo — no dose upcharges
- $4.60 EPC #2 in stack
- 1.31% conversion rate
Watch for
- Month-to-month price ($299) higher than TMates annual ($158)
- Gum format not clinically equivalent to injectable
Eden Health
Widest Medication MenuCompounded sema $229–$249/mo · Branded Ozempic/Wegovy + compounded depending on insurance
Eden is the only provider in our stack offering both branded GLP-1 (Ozempic, Wegovy, Mounjaro, Zepbound) alongside compounded options — useful for patients who want to start compounded and may switch to branded. Also has the broadest wellness stack (NAD+ 5-format menu, peptides, hormones).
Notable for
- Only provider offering branded + compounded side-by-side
- Broadest wellness menu (NAD+, peptides, hormones)
- Insurance pathways for branded GLP-1
Watch for
- Compounded sema at $229–$249/mo — higher than TMates/Strut
- Lower affiliate EPC than TMates
Compounded vs Branded Semaglutide: How to Choose
This is a clinical decision between you and your prescriber. The table below summarizes the tradeoffs — not a recommendation for either path.
| Factor | Compounded Semaglutide | Branded Ozempic / Wegovy |
|---|---|---|
| Monthly cost | $99–$249/mo (verified) | $800–$1,400+/mo (retail, without insurance) |
| FDA approval status | NOT FDA-approved | FDA-approved (STEP-1 through STEP-8 trials) |
| Clinical evidence | No head-to-head vs branded | Robust RCT data — 15–17% avg weight loss in trials |
| Legal availability | Narrowed since March 2025 / April 2026 | Always available with prescription |
| Insurance coverage | Typically not covered | Coverage varies — prior auth often required |
| Manufacturing oversight | 503A/503B pharmacy standards | FDA-regulated GMP manufacturing |
| Format options | Injectable + oral (sublingual/gum) | Auto-injector pen only |
| Switching to branded later | Possible — ask provider | Always available |
Important: This comparison is for informational purposes only and does not constitute medical advice. The right choice depends on your health history, insurance status, and prescriber recommendation. See our medical disclaimer.
Compounded Semaglutide vs Compounded Tirzepatide
Tirzepatide (Mounjaro/Zepbound's active ingredient) outperformed semaglutide on average weight loss in the SURMOUNT-5 head-to-head trial (NEJM, 2025) — 20.2% vs 13.7% at 72 weeks in adults with obesity without diabetes. However, regulatory positions differ: compounded tirzepatide's shortage ended October 2024 with a longer enforcement runway than semaglutide (shortage resolved March 2025 with tighter timeline). Both are restricted as of April 2026, but the specific pathways and risk profiles differ.
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Compounded semaglutide is in a more restricted position than compounded tirzepatide in 2026. The FDA officially declared the semaglutide shortage resolved in March 2025 — earlier than tirzepatide. This triggered a tighter enforcement timeline. As of April 1, 2026, FDA enforcement discretion for 503A pharmacies compounding copies of branded semaglutide (Ozempic, Wegovy) at telehealth scale has ended. 503A pharmacies may still compound patient-specific formulations with a documented clinical justification (allergy, custom strength, or other PCAB criterion). Personalized compounded semaglutide with unique clinical rationale may still be available. 503B outsourcing facilities are the subject of a separate FDA proposal (April 30, 2026) that would restrict bulk semaglutide use. Always confirm current status with the specific telehealth provider before prescribing or ordering.
How much does compounded semaglutide cost in 2026?
Verified pricing across active providers as of May 2026: Strut Health offers oral compounded semaglutide from $99/mo on auto-refill (lowest verified entry tier). TMates offers injectable + oral semaglutide from $158/mo on a 12-month plan ($249 month-to-month). Embody offers a GLP-1 gum format at $149 first month / $299 flat refills. Eden Health offers compounded semaglutide at $229–$249/mo. These prices are for compounded semaglutide, not branded Ozempic or Wegovy, which typically cost $800–$1,400+/mo without insurance.
What is the difference between compounded semaglutide and Ozempic or Wegovy?
Ozempic and Wegovy are FDA-approved brand-name drugs manufactured by Novo Nordisk. Compounded semaglutide is produced by state-licensed compounding pharmacies under FDA exemptions — it is NOT FDA-approved. Compounded semaglutide may use the same active ingredient (semaglutide) but differs in formulation, manufacturing oversight, excipients, and quality controls. Branded products undergo rigorous clinical trials and manufacturing audits; compounded products do not. Branded GLP-1s are the clinical standard. Compounded versions are typically chosen for cost reasons. This distinction matters clinically — discuss with your physician.
What happened to compounded semaglutide after the FDA shortage ended?
In March 2025, the FDA formally declared the semaglutide shortage resolved, removing the primary legal basis for 503A pharmacies to compound copies at scale. Unlike tirzepatide (shortage resolved October 2024 with a longer enforcement runway), semaglutide had a shorter transition window. By April 1, 2026, general telehealth-scale compounding of semaglutide copies has become enforcement-risk territory for 503A pharmacies. Providers still operating in this space are relying on narrow clinical exception pathways. Confirm the specific legal basis with your provider before ordering.
Can I still get compounded semaglutide through a telehealth provider?
As of May 2026, several telehealth providers in our active stack are still offering compounded semaglutide programs. Strut Health ($99/mo), TMates ($158/mo annual), Embody ($149 intro), and Eden Health ($229–$249/mo) all offer compounded or low-cost semaglutide options. Legal availability varies by state, pharmacy, and the specific clinical justification pathway. Always ask the provider directly about the regulatory basis for their compounded GLP-1 program before enrolling.
Is oral (sublingual) compounded semaglutide as effective as injectable?
There are no published head-to-head randomized controlled trials comparing oral compounded semaglutide to FDA-approved injectable semaglutide (Ozempic/Wegovy). Oral bioavailability of peptides is generally lower than subcutaneous injection. The FDA-approved oral semaglutide (Rybelsus) is formulated with a specific absorption enhancer (SNAC) at carefully calibrated doses — this formulation is proprietary. Compounded oral semaglutide preparations are not equivalent and have not been tested for equivalent efficacy. Discuss the format with your prescribing physician.
Ready to Compare Programs?
Our verified stack has programs from $99/mo. Check eligibility and pricing in minutes — no video visit required at most providers.
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.
Related Guides
Continue your research with these related independent reviews.